InflaRx N.V. (IFRX) AI Stock Analysis

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing inhibitors using C5a technology to address severe autoimmune and inflammatory conditions. Its lead product candidate is vilobelimab, an intravenously delivered anti-C5a monoclonal antibody that completed Phase III clinical trials for hidradenitis suppurativa and is in Phase II trials for pyoderma gangraenosum and ANCA-associated vasculitis. The company is also advancing INF904, an oral small molecule, and IFX002 in pre-clinical development. InflaRx supports its pipeline through strategic alliances, including collaborations with Beijing Defengrei Biotechnology Co. Ltd. and Merck & Co. Inc.

As a clinical-stage biotechnology firm, InflaRx generates negligible commercial revenue, which stood at $29,331 in FY2025 after falling 82.3% from $165,789 in FY2024. Net loss was -$45.6M in FY2025, compared to -$46.1M in FY2024 and -$42.7M in FY2023, largely driven by research and development expenditures of $25.7M in FY2025. Over the 3-year period from FY2017 to FY2025, revenue posted a CAGR of -49.7%. For the trailing twelve months ended June 30, 2026, revenue was -$10,101 with EPS of -$0.58, while latest quarterly revenue fell 80.8% year-over-year.

As of June 30, 2026, InflaRx held $158.4M in cash and short-term investments against total debt of $832,833, resulting in net cash of $157.6M. The company shows a current ratio of 8.22 and a debt-to-equity ratio of 0.01 on shareholders' equity of $146.1M. Operating cash flow for FY2025 was -$33.9M, producing free cash flow of -$34.0M after capital expenditures of $111,127. Over the past five years, the company's share count expanded by 182.6%.

InflaRx trades at a market capitalization of $194.5M and an enterprise value of $108.3M, with a price-to-book ratio of 1.7x and an EV/EBITDA of 0.5x, well below the 12.0x EV/EBITDA median of its US-listed Healthcare peers. The stock closed at $1.32 on October 16, 2026, sitting 18.1% below its 200-day moving average. Shares have gained 6.5% over the past year, trailing the S&P 500's 16.8% return, and are down 46.6% over five years compared to an 83.0% gain for the index.

Wall Street sentiment is positive, with 7 Strong Buy, 1 Buy, and 1 Hold ratings. The mean price target is $7.68, representing a 481.9% premium over the last close of $1.32. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $0 and an EPS of -$0.27. Next fiscal year estimates from 5 analysts also project $0 in revenue and an EPS of -$0.35. InflaRx has beaten EPS estimates in 1 of the last 4 quarters, with its next earnings scheduled for November 9, 2026.

This page is an AI-written research summary of InflaRx N.V. (IFRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IFRX income statement, IFRX balance sheet, IFRX key metrics, IFRX analyst forecast, IFRX chart. See the IFRX stock overview for the latest quote and news.